Some who receive a new liver carry an old fear: that the cancer which once threatened them may quietly return. In a small study of thirty-eight transplant recipients in Houston, researchers tested whether fragments of tumor DNA drifting in the blood could reveal such a return sooner than the scans and markers now relied upon. The early picture is one of promise tempered by honesty: the test never raised a false alarm where it was properly applied, yet it found only half of the recurrences that imaging confirmed. Medicine, like any careful witness, now waits for larger and more varied evidence
Blood Test Shows Promise for Early Detection of Liver Cancer Recurrence After Transplant
The blood test flagged half of the recurrences that imaging confirmed.
Mark
So what exactly did the researchers do here?
Mimi
They followed 38 liver transplant recipients and ran a personalized ctDNA blood test next to the usual monitoring, imaging and tumor markers. They analyzed over 720 samples in all.
Mark
And why does catching recurrence early matter so much in this group?
Mimi
Dr. Abdelrahim says recurrence is common and outcomes are poor when the cancer comes back. Earlier detection means doctors can act sooner and watch patients more closely.
Luke
Before we get excited, how well did it actually work?
Mimi
Imaging found recurrence in six patients. The blood test was positive in three of them. In the other three it was negative or there wasn't enough DNA to process.
Luke
So it caught half. That's a small number to hang much on.
Mimi
Agreed. And the headline strength is specificity, 100 percent, meaning no false positives. But that applies to patients with adequate testing.
Mark
Does that mean the test could replace invasive procedures?
Luke
The study says it may help reduce the need for them. That's a possibility, not something shown here. The source doesn't report any procedures actually avoided.
Mimi
The researchers say as much. They want other scientists to run more studies before clinics adopt it.
Luke
And the 38-patient size is the limit. Largest in the U.S. so far, but still small.
O Pulso
- A recurrence of liver cancer after transplant threatens patients whose survival depends on catching it early.
- Imaging found six returning cancers, and the new blood test matched only three of them, leaving real gaps in detection.
- Researchers are testing a personalized ctDNA blood draw alongside standard scans to reduce dependence on invasive monitoring.
- Among patients with adequate samples, the test produced zero false positives, a clean signal that now needs confirmation.
- The findings remain preliminary, and clinical adoption awaits larger studies by independent scientists.
Some who receive a new liver carry an old fear: that the cancer which once threatened them may quietly return. In a small study of thirty-eight transplant recipients in Houston, researchers tested whether fragments of tumor DNA drifting in the blood could reveal such a return sooner than the scans and markers now relied upon. The early picture is one of promise tempered by honesty: the test never raised a false alarm where it was properly applied, yet it found only half of the recurrences that imaging confirmed. Medicine, like any careful witness, now waits for larger and more varied evidence before deciding whether this quiet method will earn a place at the bedside.
Thirty-eight people who had received new livers gave blood over the course of a Houston Methodist study, and researchers examined more than 720 samples in total. The question at the center was simple and urgent: could a personalized blood test spot a return of liver cancer after transplant, and do so without relying so heavily on invasive procedures?
The test searches for circulating tumor DNA, tiny fragments of cancer genetic material that move through the bloodstream. It ran alongside imaging and conventional tumor markers, the tools patients already depend on. The work, led by Dr. Maen Abdelrahim of the Houston Methodist Research Institute, was published in the Journal of Gastrointestinal Oncology.
The results are encouraging but limited. Imaging detected six recurrences. The blood test matched three of them, while the other three either came back negative or lacked enough material to analyze. In the patients whose samples were adequate, the test raised no false alarms at all.
Abdelrahim emphasized timing, noting that finding a recurrence early can change what doctors are able to do. Researchers stopped short of recommending routine use, pointing instead to the need for larger studies before the test enters clinical practice.
Thirty-eight people who had received new livers were followed in a Houston Methodist study, and each of them gave blood that researchers analyzed for traces of cancer. Over the course of the work, the team collected and examined more than 720 samples. The question was whether a personalized blood test could spot a return of liver cancer after transplant, and do it with less reliance on invasive procedures.
The test looks for circulating tumor DNA, or ctDNA: tiny fragments of cancer DNA that travel in the bloodstream. In this study it was run alongside the standard tools, which include imaging and conventional tumor markers. The findings were published in the Journal of Gastrointestinal Oncology.
The work was led by Dr. Maen Abdelrahim, who directs the Cockrell Center for Advanced Therapeutics Phase I program at the Houston Methodist Research Institute and serves as chief of GI Medical Oncology at Houston Methodist. The researchers describe it as the largest study to date in the United States on whether a personalized blood test can detect liver cancer recurrence in transplant patients. It is also the first prospective investigation of its kind in this area.
The results are mixed, and the numbers are small. Imaging detected a recurrence of cancer in six patients during the study period. In three of them, the ctDNA test was positive and matched the imaging. In the other three, the ctDNA result was either negative or there was not enough material to process. So in this sample, the blood test flagged half of the recurrences that imaging confirmed.
The test did perform cleanly in one respect. Among patients whose ctDNA testing was adequate, specificity was 100 percent, meaning no false-positive results were observed. Nobody in that group was flagged by the blood test for a cancer that was not there.
Abdelrahim framed the stakes around timing. Detecting recurrence early, he said, can change everything for people who have had a transplant, because doctors can act sooner and monitor patients more closely. Recurrence of liver cancer is common, he noted, and outcomes are poor when it returns, which is why he called the research a big step toward giving patients a better chance of survival.
The disease itself is a heavy burden worldwide. According to the American Cancer Society, more than 800,000 people are diagnosed with liver cancer each year, and more than 700,000 die from it annually, making it a leading cause of cancer deaths globally.
The researchers themselves stop short of recommending the test for routine use. They point to the need for additional studies by other scientists to build the evidence on ctDNA testing before it is adopted in clinics. What to watch for is whether larger studies confirm the clean specificity and improve on the three recurrences the test did not catch.
Citações Notáveis
Detecting cancer recurrence early can change everything, especially among the post-transplant population.— Dr. Maen Abdelrahim, Houston Methodist
Quer a matéria completa?
Leia o original em Medical Xpress ↗
Science & Space